01 August 2018
Visiongain’ has launched a new pharma report Global Translational Regenerative Medicine Market Prospects 2018-2028: Stem Cell Therapies, Tissue Engineered Products, Gene Therapies.
Regenerative medicine has been undergoing a period of sustained innovation over the last two decades. Tissue engineering and stem cell research in particular have seen a level of interest which it hasn’t received for a long while. Novel cell sources such as induced pluripotent stem cells have also helped to open new areas of research which had previously seemed impossible due to limited resources. There are potential opportunities in the market for participating companies, however certain risks and limitations also abound. The global regulations surrounding regenerative medicine remains fragmented. The changes to regulatory processes in the leading national and regional markets should help to drive progress in the regenerative medicine market.
The lead analyst of the report commented “Growth in the global translational regenerative medicine market will be fuelled particularly by stem cell therapies and tissue engineering advancements, as well as the emergence of commercial gene therapy products. The improvements in regulation of stem cell research on a regional level will increase its attractiveness. We note that advancements such as 3D bioprinting should enable the development of tissues which can be used for toxicology testing purposes.
Furthermore, strong government support for regenerative medicine particularly in countries such as China and South Korea, as well as the accelerated regulatory pathway for regenerative medicine in Japan will drive the growth in stem cell therapies.”
Leading companies featured in the report include Alphatec Spine, Anterogen, Athersys, Avita Medical, AxoGen, Medipost, Mesoblast, NuVasive, Ocata Therapeutics, Organogenesis, Pharmicell, Regenerys, TiGenix, UniQure, Vericel Corporation
Notes for Editors
If you are interested in a more detailed overview of this report, please send an e-mail to firstname.lastname@example.org or call her on +44 (0) 20 7549 9987
Visiongain is one of the fastest-growing and most innovative independent media companies in Europe. Based in London, UK, visiongain produces a host of business-to-business reports cusing on the automotive, aviation, chemicals, cyber, defence, energy, food & drink, materials, packaging, pharmaceutical and utilities sectors.
Visiongain publishes reports produced by analysts who are qualified experts in their field. Visiongain has firmly established itself as the first port of call for the business professional who needs independent, high-quality, original material to rely and depend on.
Although price is still the most important competitive advantage for a biosimilar company, current discount rates are not enough to automatically convince the key stakeholders of a biosimilar’s value.
10 September 2019
The global anti-infective agents market is one that is driven by innovation. This is vital for maintaining the rich pipeline of anti-infective agents seen in the market today.
09 September 2019
Thyroid disease is one of today’s most prevalent hormonal illnesses. Hyperthyroidism, hypothyroidism, and thyroid nodules are the most common thyroid gland disorders.
05 September 2019
Somatostatin was used to diagnose gastrointestinal tract tumors and acromegaly in the clinical environment.